ArticleCureus2025
Elucidating the Role of MicroRNAs in Regulating Insulin Signaling Pathways: Implications for the Pathophysiology and Treatment of Type 2 Diabetes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This retrospective cross-sectional analysis assessed the regulatory role of microRNA-375 (miR-375) in the insulin signaling pathway and its clinical relevance for the treatment of type 2 diabetes mellitus (T2DM) in a Pakistani cohort. Methodology The study analyzed data from 300 adult patients with clinically confirmed T2DM to identify associations between miR-375 expression levels, insulin signaling pathway-specific biomarkers, glycemic indices, and treatment response. Results The mean miR-375 levels were found to be inversely correlated with HbA1c (r = -0.31, p < 0.01) and positively correlated with both insulin receptor substrate 1 expression (r = 0.29, p < 0.01) and phosphoinositide 3-kinase activity (r = 0.25, p < 0.01), indicating a proportionately enhanced insulin sensitivity with increased miR-375 expression. The one-way analysis of variance revealed significant differences in the expression of glucose transporter type 4 (GLUT4) between the three therapy response groups, with improved therapy responders displaying higher GLUT4 levels (p = 0.012). Logistic regression models identified miR-375 (odds ratio (OR) = 0.71, p < 0.05) and Framingham Risk Score (OR = 1.46, p < 0.001) as microRNA and clinical predictors, respectively, for cardiovascular disease, indicating its promise as a potential predictive biomarker. Hierarchical k-means clustering identified distinct patient subtypes to identify a high-risk patient profile based on insulin signaling and treatment adherence behaviors. Cluster 1, with high miR-375 and insulin sensitivity indicators, was associated with superior glycemic management and fewer comorbidities among participants in the study. Conclusions The results support the incorporation of miR-375 profiling in clinical practice to improve therapeutic stratification for T2DM by providing successful treatment predictions to improve metabolic outcomes. This study builds upon earlier findings and initiates a deeper understanding of miRNA-mediated modulation of the pathophysiology associated with T2DM. miR-375 is highlighted as a candidate biomarker for precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.